anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Compositions and methods for use for treating, pulmonary hypertension, in particular neonatal pulmonary hypertension and early lung inflammation, are described. In a first embodiment, the composition comprises pulmonary vasodilators and mitochondrial targeted antioxidants in mixture with a lung surfactant. Preferably, the composition comprises one or more chemicals selected from the group consisting of a long-acting nitric oxide donors, antioxidants, endothelin-1 receptor antagonists, and antithromboxanes in mixture with a lung surfactant. In a second embodiment, the present invention provides a composition for treating neonatal pulmonary hypertension and early lung inflammation in mammals who do not respond to nitric oxide treatment alone. In this embodiment, the composition comprises liposomes comprising a pulmonary or lung surfactant and which contains vasodilators and chemicals which modulate development of acute inflammation. In a preferred embodiment, the liposome contains a long-acting nitric oxide donor, a recombinant human IκB-α, an NF-κB inhibitor, an anti-TNF-α, and an iNOS inhibitor. The composition can further include one or more of the components comprising the first embodiment.
PURPOSE:The titled agent for cosmetics or medicines, prepared by adding a high polymeric stabilizer, acid activated clay, etc. in very small amounts to a colloidal solution containing (ultra)fine particles of an iron compound and a metallic salt, e.g. Na or Ca, and capable of washing effectively and activating the  skin of the human body, etc. CONSTITUTION:A liquid-phase skin activator, prepared by adding very small amounts of acid activated clay or zeolite to a colloidal metallic solution containing (ultra) fine particles of a bivalent iron compound, e.g. iron sulfide or iron  sulfate, as a principal component and (ultra)fine particles of a metallic salt of  Na, Ca, Mg, Cu or Al as a minor component, and adding a very small amount  of a high polymer for stabilizing the colloidal state to the resultant solution. A  magnetic field is generated in a site where the colloidal metallic particles are  attached to the skin, and the ionic transfer is activated by the change in the  magnetic field to further activate the cell electrically. The activator will adsorb  oxygen easily due to the colloidal bivalent metal, and the oxygen is dissolved in  the skin tissue to exterminate anaerobes, e.g. trichophytons, by keeping the skin  in aerobic conditions.
The present invention relates to a medicinal herb composition for suppressing obesity which effectively reduces body weight without side effects to a human body and is able to prevent various diseases caused by overweight or obesity. The medicinal herb composition for suppressing obesity according to the present invention contains Ephedra sinica, Atractylodes japonica, Coix lachryma-jobi L. var. ma-yuen Stapf, Rehmannia glutinosa, Crataegus pinnatifida Bunge var. typica Schneider, corn silk, pine needles, Dimocarpus longan Lour., and Poria cocas Wolf. and further contains Sinomenium acutum (Thunb.) Rehder&amp; E.H.Wilson, Citrus unshiu Markovich, Acyranthes bidentata Blume, Angelica gigas Nakai, Caesalpinia sappan L., Artemisia asiatica, Cartami semen, Acanthopanax sessiliflorum, Astragalus membranaceus BUNGE, and Glycyrrhiza uralensis Fischer.
Each subject will be participating in three study visits: Screening Visit, Visit 1: a low-dose dobutamine visit and Visit 2: a low-dose cocaine visit. At the dobutamine visit, the subject will only receive low-dose dobutamine, which will be used as an internal inotropic/vasodilator control for cocaine. At the cocaine visit, the subject will receive low-dose intranasal cocaine followed by either the active study drug (dexmedetomidine) or an inactive placebo (saline). Both cocaine and dobutamine will increase myocardial contractility and oxygen demand, thereby stimulating metabolic vasodilation. If, as predicted, cocaine also causes α-adrenergic agonist in the coronary microcirculation, then myocardial blood flow should increase less with cocaine then with dobutamine for a given level of myocardial oxygen demand. We will study if dexmedetomidine, a central sympatholytic, can normalize this cocaine effect. We previously have used dobutamine as a comparator for cocaine in our research. At both visits, myocardial contrast echocardiography will be used to measure regional myocardial perfusion.
Optimizing uptake of HIV testing is critical to meeting 95-95-95 goals in sub-Saharan Africa. As 30% of new infections in occur within married or cohabitating couples, maximizing testing among individuals who are or may someday be in serious heterosexual relationships has been identified as one of the most cost-effective strategies to curb the epidemic. Childbearing is highly valued throughout Sub-Saharan Africa, and fears of relationship dissolution and loss of the ability to have children remain significant barriers to HIV testing. The expanding availability of pre-exposure prophylaxis (PrEP) presents an opportunity to counter these fears with strategic communication (NOT-MH-21-105) that reassure couples of their ability to have a healthy family even if one or both members are HIV positive. Our long-term objective is to leverage the growing availability of PrEP to determine if and how a communication strategy focused on relationship preservation and safer conception can increase testing and entry into treatment (antiretroviral therapy) or prevention (PrEP) among partnered individuals in Uganda. We recently successfully piloted this communication strategy within Uganda's assisted partner notification program (APN). In this R34, we will: (1) conduct formative research to expand the communication strategy into a multi-component intervention with broader reach; and (2) conduct a pilot trial of the intervention, PrEPing Healthy Families. To achieve Aim 1, we will work with a community advisory board (CAB) of providers to a) create communication materials (brochures, scripts) and counseling protocols tailored to clients and partners across the array of couples' testing pathways in APN and antenatal care (ANC). As CAB providers pilot materials and tracking systems with clients and partners during this development phase, study staff will conduct field observations and qualitative interviews focused on feasibility and acceptability, informing revised intervention materials. To achieve Aim 2, we will collect baseline data at APN and ANC clinics within two large public healthcare facilities over nine months. Sites will then be randomized to implement PrEPing Healthy Families or their existing communication approach (usual care) over the next nine months. We will collect mixed-methods data on feasibility and acceptability through intervention tracking in APN/ANC registers, client exit surveys, and qualitative interviews with clients, partners and providers. Through register extraction, we will examine limited efficacy on outcomes that would be relevant to a larger trial (partner HIV testing, client service uptake initiation of PrEP/ART), and explore potential moderators. Overall, results will yield important insights in a promising new communication strategy (NOT-MH-21-105) that may connect more individuals to the HIV cascades of care for treatment or prevention and prepare us for a large-scale, cluster randomized controlled trial to determine impact on testing and initiation of PrEP/ART.
This study will develop and experimentally test the efficiency of a neurofeedback(NF) training protocol for smoking cessation. As non-pharmacological, non-invasive and painless brainwave technique, NF contributes to teach individuals how they can take the control of their mind through operant conditioning. NF regulates brain function in natural way. Studies have reported an 80% rate of reducing or eliminating the need for traditional medication14. Therefore, other nicotine substitutes (such as varenicline) which may carry their own toxicity risk factor may become redundant. The protocol will include 5 bio- and 25 Neuro-feedback sessions, lasting approximately 36 months.

The electrophysiological evaluation of the efficacy of the intervention will include EEG resting state and a multifeature Mismatch Negativity (MMN) evoked response measurements before and after the participation of human volunteers. These data will be analyzed in terms of cortical activation patterns and cortical connectivity. Questionnaires will be used to collect behavioral and psychometric data regarding smoking related behaviors. Additionally, a clinical evaluation including spirometry, exhaled carbon monoxide, total antioxidant capacity, vitamine E, and cotinine will be conducted. The data will be collected prior, during, after the completion of the study and after a one-year follow up.

The Neurofeedback intervention will be compared to a different group of participants that will follow an intervention based on varenicline use for approximately 3 months. The electrophysiological evaluation of the efficacy of the intervention will include EEG resting state and a sleep polysomnography measurement. Questionnaires and clinical evaluation include the same measurements as the neurofeedback intervention but only in 3 time points: prior, during, after the completion of the study.
The disclosure relates to a multi-mode disease auxiliary diagnosis method and device based on real handwriting interaction. Wherein the method comprises the following steps: based on the application information of the preset object handwriting, the data acquisition is carried out on the handwriting information of the acquisition object, so that the acquisition data information is generated. And generating a multi-mode characteristic value by carrying out preset multi-dimensional data extraction processing on the acquired data information. And based on a significance hypothesis testing method, calculating a correlation coefficient between the multi-mode characteristic value and a preset disease to generate a weighted characteristic value data set. And constructing a typical classification model based on the weighted characteristic value data set to generate a machine learning classification model, and completing auxiliary diagnosis of the diseases based on the machine learning classification model. The method and the device enable the patient with the disease to be more easily accepted in sample collection through the sampling mode, and enable the evaluation result to be more accurate and intelligent through multi-mode feature extraction.
According to the NET manual (one lifeline session and 7 exposure sessions; see Schauer et al. 2011).
In clinical trials of lixisenatide there have been cases of anaphylaxis (frequency of 0.1% or 10 cases per 10,000 patient-years) and other serious hypersensitivity reactions including angioedema. Severe, life-threatening, generalized allergic reactions, including anaphylaxis, generalized skin reactions, angioedema, bronchospasm, hypotension, and shock can occur with insulins, including insulin glargine. There have been postmarketing reports of serious hypersensitivity reactions, including anaphylactic reactions and angioedema, in patients treated with SOLIQUA 100/33 [see Adverse Reactions (6.1)].

Inform and closely monitor patients with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist for allergic reactions, because it is unknown whether such patients will be predisposed to anaphylaxis with SOLIQUA 100/33. SOLIQUA 100/33 is contraindicated in patients with known serious hypersensitivity to lixisenatide or insulin glargine [see Contraindications (4)]. If a hypersensitivity reaction occurs, the patient should discontinue SOLIQUA 100/33 and promptly seek medical attention.
The utility model relates to a chewing block for rapidly cleaning an oral cavity and tooth, belonging to the technical field of the health care and the sanitary technology of the oral cavity and the tooth. The utility model is characterized in that chemical articles 3 for cleaning, deodorizing, sterilizing, etc., are arranged in a diaphragm 2. A spongy-shaped colloid 1 is wrapped outside the diaphragm 2. The utility model has the advantages that the chewing block can not injure periodontal muscle tissue. Periodontal diseases can be relieved. The defects of the repeated infection of bacteria on a toothbrush and a tooth cup. The chewing block can be used at any time and is not limited by the time. Chewing block is beneficial to be used under special occasions and environments by children, old people, and disabled persons.
Rhinosinusitis is one of the most prevalent diseases in the United States with an estimated 31 million adults diagnosed with this condition. The annual health care burden has been estimated to exceed 5.8 billion dollars. Unfortunately, the underlying etiology of rhinosinusitis is not fully understood and may encompass multiple factors including: anatomic variations, impaired immune function, ciliary dysfunction, seasonal allergies, aspirin allergy, and bacterial biofilms. There are a wide variety of treatment options aimed at reducing the symptoms of rhinosinusitis with nasal saline irrigations (NSI) being one of the foundations for therapeutic intervention.

The benefits of NSI in rhinosinusitis in reducing nasal symptoms have been demonstrated in multiple reports. The mechanisms in which NSI exerts its beneficial effects are not fully understood, though multiple theories exist including: improvement in mucociliary function, decreased nasal mucosal edema, and removal of infectious debris and allergens. NSI are administered intranasally with the use of an irrigation bottle with a wide variety of brands commercially available for patients to select. In the Department of Otolaryngology-Head and Neck Surgery Clinic at the University of Virginia Health System, NeiMed bottles are provided to patients who are diagnosed with rhinosinusitis. In addition, the patients are given an informational sheet regarding the care and cleaning of these irrigation bottles. Unfortunately, irrigation bottles can become colonized with bacteria including: Staphylococcus aureus, Streptococcus pneumonia, Pseudomonas aeruginosa, and Candida species. The contamination of irrigation bottles can be a nidus for continued bacterial introduction into the nasal cavity and therefore decreasing the beneficial effects of NSI.

Recently, a novel commercially available irrigation solution, the ChitoRhino, has been developed with chitosan, a natural polysaccharide demonstrated to have antibacterial and antifungal properties. This polysaccharide has beneficial properties in multiple clinic applications including wound healing and post-operative sinus surgery. Chitosan's antimicrobial function develops from its polycationic structure. Chitosan interacts with the negatively charge bacterial wall, leading to disruption and cell lysis. There is a paucity of literature examining the beneficial effect of chitosan in decreasing bacterial contamination in irrigation bottles. This project represents a pilot study investigating the antimicrobial effects of chitosan in irrigation bottles for patients with rhinosinusitis.
The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.
1-(2-Hydroxy ethyl)-5-nitroimidazole is prepared by heating 4-nitroimidazole with freshly distilled ethylene chlorohydrin. The product can be converted into an acid-addition salt, e.g. hydrochloride, hydrobromide, sulphate, nitrate, acetate, embonate or picrate, by reaction with excess acid in an organic solvent. The free base and its addition salts are used in controlling turkey blackhead (see Division A5).ALSO:Compositions for the treatment and prevention of turkey blackhead comprise as active ingredient 1 - (2 - hydroxyethyl) - 5 - nitroimidazole or a non-toxic acid-addition salt thereof together with a suitable diluent or carrier for oral administration.  Addition salts specified are the hydrochloride, hydrobromide, sulphate, nitrate, acetate, embonate and picrate. The active ingredient may be administered in turkey feed or drinking water, and a premix for subsequent dilution may be obtained by admixing the active ingredient with a grain carrier. In an example, the effectiveness of 1-(2-hydroxyethyl) - 5 - nitroimidazole is compared with that of the corresponding 2-methyl-derivative.  (For the preparation of the active ingredient see Division C2).
Risk Summary

Lactation studies have not been conducted with UCERIS or other oral budesonide products and no information is available on the effects of budesonide on the breastfed infant or the effects of the drug on milk production. One published study reports that budesonide is present in human milk following maternal inhalation of budesonide (see Data). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for UCERIS and any potential adverse effects on the breastfed infant from UCERIS, or from the underlying maternal condition. 

Data

One published study reports that budesonide is present in human milk following maternal inhalation of budesonide which resulted in infant doses approximately 0.3% to 1% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 0.4 and 0.5. Budesonide plasma concentrations were not detected, and no adverse events were noted in the breastfed infants following maternal use of inhaled budesonide. The recommended daily dose of UCERIS is higher (9 mg daily) compared with inhaled budesonide (up to 800 mcg daily) given to mothers in the above described study. The maximum budesonide plasma concentration following a 9 mg daily dose (in both single- and repeated-dose pharmacokinetic studies) of oral budesonide is approximately 5 to 10 nmol/L which is up to 10 times higher than the 1 to 2 nmol/L for a 800 mcg daily dose of inhaled budesonide at steady state in the above inhalation study. Assuming the coefficient of extrapolation between the inhaled and oral doses is constant across all dose levels, at therapeutic doses of UCERIS, budesonide exposure to the nursing child may be up to 10 times higher than that by budesonide inhalation.
ABSTRACT           Compounds of general formula I,                 (I) wherein A and B, which may be the same or different, each re-presents a ethylene or ethylene group optionally substi-tuted by an alkyl group with 1 to 3 carbon atoms; R1 represents a hydrogen atom; an alkyl group with 4 to 6 carbon atoms; a cycloalkyl group with ? to 7 carbon atoms; an alkenyl group with 3 to 6 carbon atoms; an alkyl or alkanoyl group with 1 to 3 carbon atoms (optionally substi-tuted by a phenyl group which optionally may itself be sub-stituted by a halogen atom); an alkoxycarbonyl group with ? to 4 carbon atoms; an aralkoxycarbonyl group with ? to 10 carbon atoms; or a phenyl group;      one of ? an R3 represents an amino group and the other represents a hydrogen, chlorine or bromine atom, an alkyl group with 1 to 3 carbon atoms, an alkoxy group with 1 to ? atoms or a phenyl or halophenyl group;      and acid addition salts thereof, of use in lowering heart rate and influencing blood pressure.
For inhibition of muscle activity (G2 group), the Kinesio Taping® bandage will be placed over the muscle starting at the insertion location and ending at the muscle origin. Bandage in group G2 will be applied following the protocol proposed by method of technical, which defined the direction of the bandage and an applied tension of 10% to 15% (paper off). With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
PURPOSE:To obtain a cosmetic, containing acetylated saccharides readily available from saccharides having a relatively low molecular weight at a low cost and capable of forming nonaqueous cured films. CONSTITUTION:Saccharides having 300-10,000mol.wt. (e.g. saccharides extracted from Ophiogonis Tuber or inulin) are dissolved in, e.g. DMF, and then pyridine and acetic anhydride are added to allow the resultant blend to stand at room temperature for a whole day and night. Water is subsequently added to afford acetylated saccharides, which are used as a cosmetic or further medicines, agricultural chemicals, coatings, etc. The above-mentioned acetylated saccharides are obtained as white powder and insoluble in water, but is dissolved in a water-immiscible organic solvent (e.g. benzene, toluene or chloroform) to form nonaqueous cured films, having excellent adhesion (adhesive property) on, e.g. surfaces of nails, and hardly peeled.
Patients receive uniformly-labeled \[13C\]glucose IV over 10 minutes and then over up to 120 minutes until time of biopsy. Patients then undergo surgery and biopsy per standard of care.
REACCIONES ADVERSAS: Las reacciones adversas que acompañan el uso de formulaciones de sulfato de bario son infrecuentes y generalmente leves, aunque se han producido reacciones graves (aproximadamente 1 en 500,000) y muertes (aproximadamente 1 en 2,000,000). Las complicaciones del procedimiento son raras, pero pueden incluir neumonitis por aspiración, impactación con sulfato de bario, formación de granuloma, intravasación, embolización y peritonitis después de perforación intestinal, episodios vasovagales y sincopales y muertes. Se ha demostrado que los cambios de EKG ocurren después o durante los enemas de suspensión de sulfato de bario. Es de la mayor importancia estar completamente preparado para tratar cualquier evento de este tipo.

Debido a la mayor probabilidad de reacciones alérgicas en pacientes atópicos, un historial completo de alergias conocidas y sospechadas, así como síntomas de tipo alérgico, p. rinitis, asma bronquial, eczema y urticaria, deben obtenerse antes de cualquier procedimiento médico.

La aspiración de grandes cantidades de suspensión de sulfato de bario puede causar neumonitis o granulomas nodulares de tejidos pulmonares intersticiales y ganglios linfáticos; asfixia y muerte han sido reportadas.

La bacteriemia transitoria puede ocurrir durante la administración rectal de la suspensión de sulfato de bario, y se ha informado de septicemia.

Una reacción alérgica leve y poco común sería la prurito generalizada, el eritema o la urticaria (aproximadamente 1 de cada 100.000 reacciones). Tales reacciones a menudo responderán a un antihistamínico. Las reacciones más graves (aproximadamente 1 en 500,000) pueden causar edema laríngeo, broncoespasmo o hipotensión.

Las reacciones graves que pueden requerir medidas de emergencia a menudo se caracterizan por vasodilatación periférica, hipotensión, taquicardia refleja, disnea, broncoespasmo, agitación, confusión y cianosis, que progresa hasta la inconsciencia. El tratamiento debe iniciarse de inmediato de acuerdo con el estándar de atención establecido.

Los pacientes aprensivos pueden desarrollar debilidad, palidez, tinnitus, diaforesis y bradicardia después de la administración de cualquier agente de diagnóstico. Tales reacciones son generalmente de naturaleza no alérgica.
Patients receive ipilimumab IV over 90 minutes on day 1 and nivolumab as Arm A. Treatment repeats every 2 weeks for up to 3 cycles for nivolumab in the absence of disease progression or unacceptable toxicity. Patients undergo liver surgery on day 1 of week 7. Beginning 4 weeks after surgery, patients receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.